H.C. Wainwright raised the firm’s price target on Merus to $85 from $65 and keeps a Buy rating on the shares. The additional details from the ongoing Phase 1/2 study of petosemtamab in combination with pembrolizumab further de-risks the head and neck squamous cell carcinoma opportunity by reporting a broad diversity of responses, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus N.V. Announces Proposed Public Offering of Common Shares
- Merus data coming early nothing to be worried about, says Truist
- Merus abstract shows ‘stellar potential’ of petosemtamab, says H.C. Wainwright
- Merus price target raised to $61 from $52 at BofA
- Merus announces publication of abstract on Petosemtamab at ASCO